HomeCompareSCRYY vs MRK

SCRYY vs MRK: Dividend Comparison 2026

SCRYY yields 6.25% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $36.0K in total portfolio value
10 years
SCRYY
SCRYY
● Live price
6.25%
Share price
$3.26
Annual div
$0.20
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$0.64
Full SCRYY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SCRYY vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCRYYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCRYY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCRYY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCRYY
Annual income on $10K today (after 15% tax)
$531.33/yr
After 10yr DRIP, annual income (after tax)
$0.54/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,327.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCRYY + MRK for your $10,000?

SCRYY: 50%MRK: 50%
100% MRK50/50100% SCRYY
Portfolio after 10yr
$38.8K
Annual income
$4,899.39/yr
Blended yield
12.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SCRYY
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
2.6
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCRYY buys
0
MRK buys
0
No recent congressional trades found for SCRYY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCRYYMRK
Forward yield6.25%2.76%
Annual dividend / share$0.20$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$20.8K$56.8K
Annual income after 10y$0.64$9,798.13
Total dividends collected$636.00$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SCRYY vs MRK ($10,000, DRIP)

YearSCRYY PortfolioSCRYY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,013$312.55$11,206$366.19$193.00MRK
2$11,944$160.84$12,650$502.35$706.00MRK
3$12,862$81.52$14,407$694.19$1.5KMRK
4$13,803$41.02$16,585$967.82$2.8KMRK
5$14,790$20.57$19,342$1,363.89$4.6KMRK
6$15,836$10.30$22,913$1,947.19$7.1KMRK
7$16,949$5.15$27,662$2,823.89$10.7KMRK
8$18,138$2.58$34,159$4,173.35$16.0KMRK
9$19,409$1.29$43,337$6,308.80$23.9KMRK
10$20,769$0.64$56,776$9,798.13$36.0KMRK

SCRYY vs MRK: Complete Analysis 2026

SCRYYStock

SCOR SE, together with its subsidiaries, provides life and non-life reinsurance products in Europe, the Middle East, Africa, the Americas, Latin America, and Asia Pacific. It operates through two segments, SCOR Global P&C and SCOR Global Life. The SCOR Global P&C segment offers reinsurance products in the areas of property, motors, casualty treaties, credit and surety, decennial insurance, aviation, marine and energy, engineering, agricultural risks, and property catastrophes; specialties insurance products, including business solutions, political and credit risks, cyber, and environmental impairment liability; and business ventures and partnerships. The SCOR Global Life segment provides life reinsurance products, including protection for mortality, morbidity, behavioral risks, disability, long-term care, critical illness, medical, and personal accident. This segment also provides financial solutions that combine traditional life reinsurance with financial components and provide liquidity, balance sheet, solvency, and income improvements to clients; longevity solutions that include products covering the risk of negative deviation from expected results due to the insured or annuitant living longer than assumed in the pricing of insurance covers provided by insurers or pension funds; and distribution solutions. In addition, it is involved in the asset management business. The company was founded in 1970 and is headquartered in Paris, France.

Full SCRYY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SCRYY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCRYY vs SCHDSCRYY vs JEPISCRYY vs OSCRYY vs KOSCRYY vs MAINSCRYY vs JNJSCRYY vs ABBVSCRYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.